Gulyaeva NV (2024) Augmented Cortisol and Antiglucocorticoid Therapy in Mood Disorders: The Hippocampus as a Potential Drug Target
The MDS-UPDRS and CDR-SB cannot cleanly separate symptomatic relief from disease modification, and EVOKE showed the converse failure mode, biomarker movement without clinical benefit, so future trials should anchor on objective measures such as dopamine-transporter SPECT, neurofilament light chain, and tau, amyloid, and neuroinflammation PET
430mg) or as otherwise directed by your physician or health care professional
Our goal is to move the field toward effective, accessible treatments that can slow or even reverse liver damage before patients reach liver failure. Co-authors include Jacob George, Westmead Institute for Medical Research
Patients who prioritize cost per kilogram of weight loss will continue to choose weekly compounded semaglutide, tirzepatide, or retatrutide regardless of which monthly drug launches first.